AR059900A1 - Anticuerpos anti-tat226 e inmunoconjugados - Google Patents
Anticuerpos anti-tat226 e inmunoconjugadosInfo
- Publication number
- AR059900A1 AR059900A1 ARP070101054A ARP070101054A AR059900A1 AR 059900 A1 AR059900 A1 AR 059900A1 AR P070101054 A ARP070101054 A AR P070101054A AR P070101054 A ARP070101054 A AR P070101054A AR 059900 A1 AR059900 A1 AR 059900A1
- Authority
- AR
- Argentina
- Prior art keywords
- hvr
- sequence
- amino acid
- acid sequence
- tat226
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Se proporcionan anticuerpos anti-TAT226 e inmunoconjugados de los mismos. Se proporcionan métodos de uso de los anticuerpos anti-TAT226 y de los inmunoconjugados de los mismos. Reivindicacion 1: Un anticuerpo que se une a TAT226, donde el anticuerpo comprende (a) una HVR-H3 que contiene una secuencia de aminoácidos que se adapta a la secuencia de consenso de identificador de secuencia n°: 11, y (b) al menos una, dos, tres, cuatro o cinco HVR seleccionadas entre: (1) una HVR-H1 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 4; (2) una HVR-H2 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 5; (3) una HVR-L1 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 12; (4) una HVR-L2 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 13 y (5) una HVR-L3 que comprenda una secuencia de aminoácidos que se adapte a la secuencia de consenso de identificador de secuencia n°: 19. Reivindicacion 39: Un método de deteccion de la presencia de TAT226 en una muestra biologica y dicho método comprende establecer el contacto de la muestra biologica y un anticuerpo de los indicados en las reivindicaciones 1, 16 o 30, en condiciones que faciliten la union del anticuerpo a TAT226 y detectar si un complejo está formado por el anticuerpo y TAT226. Reivindicacion 47: Un inmunoconjugado con la formula Ab-(L-D)p, donde: (a) Ab es un anticuerpo que se une a TAT226 y que comprende 1) una HVR-H3 que contiene una secuencia de aminoácidos que se adapta a la secuencia de consenso de identificador de secuencia n°: 11, y 2) al menos una, dos, tres, cuatro o cinco HVR seleccionadas entre: (i) una HVR-H1 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 4; (ii) una HVR-H2 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 5; (iii) una HVR-L1 que comprenda la secuencia de aminoácidos de identificador de secuencia n° 12; (iv) una HVR-L2 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 13; y (v) una HVR-L3 que comprenda una secuencia de aminoácidos que se adapte a la secuencia de consenso de identificador de secuencia n°: 19; (b) L es un enlazador; (c) D es un fármaco de formula DE o D y donde R2 y R6 son, cada uno, metilo; R3 y R4 son cada uno isopropilo; R7 es sec-butilo, cada R8 se selecciona independientemente entre CH3, O-CH3, OH, y H; R9 es H; R10 es aril; Z es -O- o -NH-; R11 es H, alquilo C1-8 o -(CH2)2-O-(CH2)2-O-(CH2)2-O-CH3; y R18 es -C(R8)2-(R8)2-aril; y (d) p oscila entre 1 y 8.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW96109168A TWI406871B (zh) | 2006-03-17 | 2007-03-16 | 抗tat226抗體及免疫接合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78374606P | 2006-03-17 | 2006-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059900A1 true AR059900A1 (es) | 2008-05-07 |
Family
ID=38255543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070101054A AR059900A1 (es) | 2006-03-17 | 2007-03-15 | Anticuerpos anti-tat226 e inmunoconjugados |
Country Status (27)
Country | Link |
---|---|
US (3) | US8183347B2 (es) |
EP (1) | EP1996625B1 (es) |
JP (2) | JP5740086B2 (es) |
KR (2) | KR20140106716A (es) |
CN (1) | CN101437852B (es) |
AR (1) | AR059900A1 (es) |
AT (1) | ATE523524T1 (es) |
AU (1) | AU2007227041B2 (es) |
BR (1) | BRPI0709306A2 (es) |
CA (1) | CA2645831C (es) |
CR (1) | CR10372A (es) |
DK (1) | DK1996625T3 (es) |
EC (1) | ECSP088831A (es) |
ES (1) | ES2373244T3 (es) |
HK (1) | HK1122052A1 (es) |
IL (1) | IL193922A (es) |
MA (1) | MA30945B1 (es) |
MX (1) | MX2008011664A (es) |
MY (1) | MY148635A (es) |
NO (1) | NO341891B1 (es) |
NZ (1) | NZ571174A (es) |
PL (1) | PL1996625T3 (es) |
PT (1) | PT1996625E (es) |
RU (1) | RU2448980C2 (es) |
UA (1) | UA98762C2 (es) |
WO (1) | WO2007109567A1 (es) |
ZA (2) | ZA200807555B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030120040A1 (en) | 2001-06-29 | 2003-06-26 | Genentech, Inc. | Secreted and Transmembrane polypeptides and nucleic acids encoding the same |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
US8288352B2 (en) | 2004-11-12 | 2012-10-16 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
USRE47223E1 (en) | 2005-06-20 | 2019-02-05 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
NZ563370A (en) | 2005-06-20 | 2010-10-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
CA2614436C (en) | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
CA2676766A1 (en) * | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-robo4 antibodies and uses therefor |
CA2683568A1 (en) | 2007-05-08 | 2008-11-20 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
JP5469600B2 (ja) | 2007-07-16 | 2014-04-16 | ジェネンテック, インコーポレイテッド | 抗CD79b抗体及びイムノコンジュゲートとその使用方法 |
TW200918089A (en) | 2007-07-16 | 2009-05-01 | Genentech Inc | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
SI2657253T1 (sl) | 2008-01-31 | 2017-10-30 | Genentech, Inc. | Protitelesa proti CD79b in imunokonjugati in postopki za uporabo |
NO2842575T3 (es) | 2008-03-18 | 2018-02-24 | ||
NZ591544A (en) * | 2008-09-30 | 2013-01-25 | Abbott Lab | Improved method of rna display |
CA2826942C (en) * | 2011-02-11 | 2021-08-03 | Memorial Sloan-Kettering Cancer Center | Hla-restricted, peptide-specific antigen binding proteins |
CA2830338C (en) * | 2011-04-01 | 2016-11-15 | Wyeth Llc | Antibody-drug conjugates |
ES2622578T3 (es) | 2011-06-10 | 2017-07-06 | Mersana Therapeutics, Inc. | Conjugados de proteína-polímero-fármaco |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US9981046B2 (en) | 2012-05-15 | 2018-05-29 | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. | Drug-conjugates, conjugation methods, and uses thereof |
AU2014331714B2 (en) | 2013-10-11 | 2019-05-02 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CN105813655B (zh) | 2013-10-11 | 2022-03-15 | 阿萨纳生物科技有限责任公司 | 蛋白-聚合物-药物缀合物 |
AU2014337317A1 (en) | 2013-10-15 | 2016-09-15 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
AU2014364812B2 (en) | 2013-12-17 | 2017-05-25 | Novartis Ag | Cytotoxic peptides and conjugates thereof |
US10562977B2 (en) * | 2014-01-29 | 2020-02-18 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof |
CA2951368A1 (en) | 2014-06-13 | 2015-12-17 | Novartis Ag | Auristatin derivatives and conjugates thereof |
PL3262071T3 (pl) | 2014-09-23 | 2020-08-10 | F. Hoffmann-La Roche Ag | Sposób stosowania immunokoniugatów anty-CD79b |
JP6871858B2 (ja) | 2015-01-28 | 2021-05-19 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | 抗体薬物コンジュゲート |
JP6644956B2 (ja) * | 2016-09-07 | 2020-02-12 | サクシン ライフサイエンシス ピーヴィーティー エルティディーSaksin Lifesciences Pvt Ltd | Vegfに対する合成の抗体およびそれらの使用 |
MX2020006822A (es) * | 2018-01-04 | 2020-09-03 | Shanghai Lumosa Therapeutics Co Ltd | Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa. |
AU2019316654B2 (en) | 2018-08-10 | 2023-04-06 | Healthall Laboratory, Inc. | Superabsorbent materials and methods of making the same |
US11925660B2 (en) | 2018-08-10 | 2024-03-12 | Simeon Investment, Inc. | Treatment for obesity with superabsorbent materials |
US11918602B2 (en) | 2018-08-10 | 2024-03-05 | Simeon Investment, Inc. | Methods for reducing cholesterol with superabsorbent materials |
US20230090552A1 (en) | 2020-01-08 | 2023-03-23 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
US11096974B1 (en) | 2020-02-07 | 2021-08-24 | Healthall Laboratory, Inc. | Superabsorbent materials and methods of making the same |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
AU4200900A (en) | 1999-04-09 | 2000-11-14 | Human Genome Sciences, Inc. | 49 human secreted proteins |
EP1192176A4 (en) | 1999-06-11 | 2003-03-05 | Human Genome Sciences Inc | 49 HUMAN SECRETED PROTEINS |
EP1067182A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Secretory protein or membrane protein |
US6720146B2 (en) | 1999-09-10 | 2004-04-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20030129192A1 (en) | 1999-09-10 | 2003-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
WO2001018046A2 (en) | 1999-09-10 | 2001-03-15 | Corixa Corporation | Ovarian tumor sequences and methods of use therefor |
US20030232056A1 (en) | 1999-09-10 | 2003-12-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6617109B1 (en) | 1999-09-10 | 2003-09-09 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20030206918A1 (en) | 1999-09-10 | 2003-11-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6613515B1 (en) | 1999-09-10 | 2003-09-02 | Corixa Corporation | Ovarian tumor sequences and methods of use therefor |
US6710170B2 (en) | 1999-09-10 | 2004-03-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
AU2001257406A1 (en) | 2000-04-26 | 2001-11-07 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941 |
EP1356092A2 (en) | 2000-05-26 | 2003-10-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20040044179A1 (en) | 2000-07-25 | 2004-03-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU2002241952A1 (en) * | 2001-01-22 | 2002-07-30 | Genta Incorporated | Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers |
EP1258255A1 (en) * | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
US20030120040A1 (en) | 2001-06-29 | 2003-06-26 | Genentech, Inc. | Secreted and Transmembrane polypeptides and nucleic acids encoding the same |
WO2003024392A2 (en) | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2003025148A2 (en) | 2001-09-19 | 2003-03-27 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
AU2003245441A1 (en) | 2002-06-12 | 2003-12-31 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
CN1389472A (zh) * | 2002-07-24 | 2003-01-08 | 中国医学科学院医药生物技术研究所 | 治疗结肠癌等消化道肿瘤的抗iv型胶原酶单抗3d6与力达霉素的免疫偶联物 |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
CN1240721C (zh) * | 2002-12-03 | 2006-02-08 | 中国医学科学院医药生物技术研究所 | 力达霉素与单克隆抗体及其Fab'片段的偶联物以及在结肠癌等肿瘤靶向治疗中的应用 |
BRPI0411852A (pt) * | 2003-06-27 | 2006-05-23 | Abgenix Inc | anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seu usos |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
-
2007
- 2007-03-15 AR ARP070101054A patent/AR059900A1/es not_active Application Discontinuation
- 2007-03-16 RU RU2008141171/10A patent/RU2448980C2/ru not_active IP Right Cessation
- 2007-03-16 AU AU2007227041A patent/AU2007227041B2/en not_active Ceased
- 2007-03-16 WO PCT/US2007/064212 patent/WO2007109567A1/en active Application Filing
- 2007-03-16 PL PL07758732T patent/PL1996625T3/pl unknown
- 2007-03-16 CN CN2007800167417A patent/CN101437852B/zh active Active
- 2007-03-16 CA CA2645831A patent/CA2645831C/en not_active Expired - Fee Related
- 2007-03-16 NZ NZ571174A patent/NZ571174A/en not_active IP Right Cessation
- 2007-03-16 UA UAA200812228A patent/UA98762C2/uk unknown
- 2007-03-16 KR KR1020147020073A patent/KR20140106716A/ko not_active Application Discontinuation
- 2007-03-16 EP EP07758732A patent/EP1996625B1/en active Active
- 2007-03-16 MX MX2008011664A patent/MX2008011664A/es active IP Right Grant
- 2007-03-16 KR KR1020087025263A patent/KR101440632B1/ko active IP Right Grant
- 2007-03-16 JP JP2009501669A patent/JP5740086B2/ja active Active
- 2007-03-16 ZA ZA200807555A patent/ZA200807555B/xx unknown
- 2007-03-16 US US11/687,309 patent/US8183347B2/en active Active
- 2007-03-16 ES ES07758732T patent/ES2373244T3/es active Active
- 2007-03-16 MY MYPI20083563A patent/MY148635A/en unknown
- 2007-03-16 BR BRPI0709306-3A patent/BRPI0709306A2/pt not_active Application Discontinuation
- 2007-03-16 AT AT07758732T patent/ATE523524T1/de active
- 2007-03-16 DK DK07758732.7T patent/DK1996625T3/da active
- 2007-03-16 PT PT07758732T patent/PT1996625E/pt unknown
-
2008
- 2008-09-04 IL IL193922A patent/IL193922A/en not_active IP Right Cessation
- 2008-09-09 ZA ZA2008/07755A patent/ZA200807755B/en unknown
- 2008-10-13 MA MA31283A patent/MA30945B1/fr unknown
- 2008-10-16 NO NO20084356A patent/NO341891B1/no not_active IP Right Cessation
- 2008-10-16 CR CR10372A patent/CR10372A/es unknown
- 2008-10-17 EC EC2008008831A patent/ECSP088831A/es unknown
-
2009
- 2009-03-17 HK HK09102552.7A patent/HK1122052A1/xx unknown
-
2012
- 2012-04-18 US US13/450,326 patent/US9109035B2/en active Active
-
2013
- 2013-02-01 JP JP2013018780A patent/JP2013138672A/ja not_active Withdrawn
-
2015
- 2015-07-01 US US14/789,873 patent/US9675707B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059900A1 (es) | Anticuerpos anti-tat226 e inmunoconjugados | |
AR065271A1 (es) | Anticuerpos anti-robo4 y sus usos | |
US10125188B2 (en) | Human antibodies to respiratory syncytial virus F protein and methods of use thereof | |
ES2834739T3 (es) | Anticuerpos anti-C10orf54 y utilizaciones de los mismos | |
HRP20211125T1 (hr) | Konjugati protutijelo-lijek koji se temelje na eribulinu i postupci uporabe | |
US9340603B2 (en) | Neutralizing anti-influenza A virus antibodies and uses thereof | |
RU2008152431A (ru) | Антитела и иммуноконъюгаты и их применения | |
AR067543A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso | |
JP2013121353A5 (es) | ||
MA35153B1 (fr) | Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants | |
BR112012026021B1 (pt) | Anticorpos, seus fragmentos de ligação ao antígeno e seus usos, composições e uso das mesmas, linhagem de células de hibridoma, kit, ácido nucleico, e vetor de expressão | |
BRPI0914012A2 (pt) | anticorpo humano, composição farmacêutica, molécula de ácido nucléico, célula, clone de célula b imortalizado, polipeptídeo imunogênico isolado ou purificado, método de inibição da infecção pelo vírus da dengue. método de tratamento da infecção pelo vírus da dengue, método de triagem de polipeptídeos, método monitoramento da qualidade das vascinas contra o vírus da dengue, vacina, uso do anticorpo e epítopo | |
AR117911A2 (es) | Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
US11421020B2 (en) | Antibodies that neutralize RSV, MPV and PVM and uses thereof | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
JP2014509835A5 (es) | ||
PE20120080A1 (es) | Anticuerpos anti-notch2 y metodos de uso | |
RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
RU2015115399A (ru) | Антигены, ассоциированные с воспалительным заболеванием кишечника | |
WO2021055329A1 (en) | Anti-cd39 antibody compositions and methods | |
WO2021142448A2 (en) | Tgf-beta inhibitors and use thereof | |
JP2012513457A (ja) | Hcv感染の治療的処置および予防のための医薬としての抗hcvモノクローナル抗体 | |
KR101561664B1 (ko) | A/h3n2 인플루엔자 바이러스의 ha 단백질에 특이적인 항체, 및 이를 생산하는 하이브리도마 세포주 | |
CA3156740A1 (en) | Anti-cd45 antibodies and conjugates thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |